NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Interventional Procedures Advisory Committee

Minutes of the Committee’s 174th meeting held at 10:30 on Thursday 11th October 2018 at NICE, 10 Spring Gardens, London, SW1A 2BU.

PRESENT:
Dr Tom Clutton-Brock (Chair)
Dr Wael Agur
Mr Jonathan Anderson
Mrs Sally Brearley
Dr Nicholas Chalmers
Dr Andrew Cook (Vice Chair) – Chair for IP1709
Mr Mahmoud Elfar
Mrs Suzanne Halliday
Mrs Rosemary Harris
Mr Anthony Hatswell
Mr Tim Jackson
Dr Tim Kinnaird
Mr Malcolm Lowe-Iauri
Dr Neil McGuire
Miss Karen Nugent
Mr Kieran Murphy
Mr Frank Smith
Dr Dhiraj Tripathi
Dr James Tysome

In Attendance
NICE Staff:
Mrs Bijal Joshi - Programme Manager, IPP
Ms Ria Skelton - Senior Medical Editor
Mrs Helen Gallo- Analyst, IPP
Professor Kevin Harris - Programme Director Clinical Advisor, IPP
Mr Azad Hussain – Administrator, IPP
Miss Chloe Kastoryano - Public Involvement Adviser, PIP
Dr Ignacio Malagon – Consultant Clinical Advisor, IPP
Professor John Powell, Consultant Clinical Advisor, IPP
Mrs Vassilia Verdiel - Analyst IPP
Mrs Lakshmi Mandava- Analyst IPP

Observers: Matthew Brown - Communications Executive – NICE
Dr Anil Gharatya – FY2 Doctor – NICE
Dr Shivali Fulchand – FY2 Doctor - NICE

Apologies: Mr Alistair Jenkins
Dr Anthony Emmerson
Dr Chris Carroll
Note: The order in which the Committee took items of business at the meeting might differ from the agenda

Meeting started: 10:37

Introduction to the meeting

The Chairman welcomed the Committee Members and observers.

The Chairman also welcomed the members of the public and company representatives present at the meeting.

Code of conduct for members of the public and company representatives attending the meeting

The Chairman outlined the code of conduct for the members of the public and company representatives attending the meeting.

1. Any Other Business

The Chairman informed the Committee of the apologies made by committee members. In addition to that the Chairman informed the Committee that Hawra Abu Gulal will be leaving NICE and Matthew Brown from the Communications team will be observing today.

Dhiraj Tripathi arrived at 10:53
Kieran Murphy arrived at 11:00

2. Minutes of previous meeting

Members accepted these as a correct record.

3. Matters arising

None

4. Agenda changes

The chairman informed the Committee the meeting will run concurrently to the agenda.

5. NICE’s Advisory Body guide to declaring a conflict of interest

The Chairman drew the Committee’s attention to NICE’s advisory body quick guide for declaring conflicts of interest.
6. **Newly Notified Procedures**

**IP664/2 Percutaneous mitral valve leaflet repair for mitral regurgitation**

The discussion on IP664/2 Percutaneous mitral valve leaflet repair for mitral regurgitation started at 10:40.

Company representatives from Abbott were present for this topic.

No conflicts of interest were declared for this procedure.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Suzanne Halliday and Robert Smith.

The Chairman declared a Part Two and Robert Smith and company representatives left the meeting at 11:27. There were no members of the public present for this topic.

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP664/2 Percutaneous mitral valve leaflet repair for mitral regurgitation ended at 12:01.

There were no company representatives or members of the public present for the next topic.

---

**IP1709 Laser treatment for an anal fistula**

The discussion on IP1709 Laser treatment for an anal fistula started at 12:02.

Tom Clutton-Brock declared a Direct, Non-financial professional interest as he is a co-recipient of an NIHR research grant looking at a method of treating this condition.

Mahmoud Elfar declared that he had been sponsored by Biomed to attend a one day meeting in Berlin to observe the use of a Diode Laser for ablation of prostate. This was considered as a **direct financial professional interest** but it was noted that it was not directly related to the procedure. He was allowed to stay for part one but left the meeting for the decision making in part two.

No other conflicts of interest were declared.

The chair Tom Clutton-Brock had a conflict of interest for this topic and left the discussion before part 1. The vice chair, Andrew Cook chaired the meeting for this item.

The Committee was reminded that equalities issues was discussed at the brief stage.
Introduced by Karen Nugent and Jonathan Anderson

The Chairman declared a Part Two at 12:32 and Mahmoud Elfar left the discussion.

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1709 Laser treatment for an anal fistula ended at 12:41

The members of the public as well as company representatives returned to the meeting at 13:20

7. Public Consultation comments

IP1690 Ex-vivo machine perfusion for extracorporeal preservation of livers for transplantation

The discussion on IP1690 Ex-vivo machine perfusion for extracorporeal preservation of livers for transplantation started at 13:21.

Company representatives from Organox and Organ-Assist were present for this topic.

Dhiraj Tripathi declared that research studies with relevance to this topic were being undertaken in the department in which he works in, but that he does not have any involvement with any of this research. This was considered an indirect interest and it was agreed that he could stay for the discussion.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Dhiraj Tripathi

The Committee considered the consultation comments and made changes to sections: title, 2.5 and 1.1

The Chairman declared a Part Two and company representatives left the meeting at 13:45

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1690 Ex-vivo machine perfusion for extracorporeal preservation of livers for transplantation ended at 13:48

The members of the public as well as company representatives returned to the meeting at 13:50
IP1033/2 Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults

The discussion on IP1033/2 Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults started at 13:51.

Company representatives from Vitalstim were present for this topic.

Kieran Murphy declared that his employer manufacturers a device which delivers electrical stimulation but not for use in the same indication, anatomical site or for the same intended purpose.

This was considered a direct non-financial professional interest and it was agreed that he could stay for the discussion.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by James Tysome

The Committee considered the consultation comments.

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:02

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1033/2 Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults ended at 14:06

The members of the public as well as company representatives returned to the meeting at 14:08

IP1097/2 Platelet-rich plasma injections for osteoarthritis of the knee

The discussion on IP1097/2 Platelet-rich plasma injections for osteoarthritis of the knee started at 14:10

Company representatives from Regenlab and Arthrex were present for this topic.

No conflicts of interest were declared for this procedure
The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock

The Committee considered the consultation comments and made changes to section 2.4.

The following study, identified during consultation, will be added to the main table of the Overview:


The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:27.

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1097/2 Platelet-rich plasma injections for osteoarthritis of the knee ended at 14:29

The members of the public as well as company representatives returned to the meeting at 14:31

IP675/2 Bronchial thermoplasty for severe asthma

The discussion on IP675/2 Bronchial thermoplasty for severe asthma started at 14:31

Company representatives from Boston Scientific were present for this topic.

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Jonathan Anderson

The Committee considered the consultation comments and made changes to sections 2.3 and 2.4 in part 1.

The following study, identified during consultation, will be added to the main table of the Overview:

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:41.

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP675/2 Bronchial thermoplasty for severe asthma ended at 14:44

8. Briefs of procedures for future assessment

IP1724 Low energy contact X-ray brachytherapy (the Papillon technique) for locally advanced, inoperable, rectal cancer

The discussion on IP1724 Low energy contact X-ray brachytherapy (the Papillon technique) for locally advanced, inoperable, rectal cancer started at 14:44

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by Karen Nugent

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1724 Low energy contact X-ray brachytherapy (the Papillon technique) for locally advanced, inoperable, rectal cancer ended at 15:01

IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for the treatment of symptomatic uterine fibroids

The discussion on IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for the treatment of symptomatic uterine fibroids started at 15:01

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by Wael Agur

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for the treatment of symptomatic uterine fibroids ended at 15:20
9. **Other meeting matters**

None

10. **Date of the next meeting**

The 175th meeting of the Interventional Procedures Advisory Committee will be held on Thursday 08th November 2018, and will start promptly at 10.30. The meeting will be held at NICE, 10 Spring Gardens, London, SW1A 2BU

The meeting ended at 15:20